Loading
A phase 1/2 trial of Mirvetuximab soravtansine in ovarian cancer, run by Takeda, active and no longer recruiting.
A Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid Tumors is a phase 1/2 interventional study registered as NCT06390995 by Takeda, with 28 participants enrolled, started 2024-05-20 and due to reach its primary completion in 2025-04-16. Interventions recorded: TAK-853. Conditions listed: Ovarian Cancer, Solid Tumors. Results were posted on ClinicalTrials.gov in 2026; the figures recorded here are the registry's, not a publication's.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
28 enrolled.
90% CI 27.0 to 62.1; Figures from the ClinicalTrials.gov results section (first posted 2026-06-16), not from a publication
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Phase 2: Objective Response Rate (ORR) Assessed by Investigator With Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)primary | Phase 2: TAK-853, 6 mg/kg | 25 | 44% | - | - | link |
Shares Mirvetuximab soravtansine, Antibody-drug conjugate (ADC), Ovarian cancer.
Shares Mirvetuximab soravtansine, Antibody-drug conjugate (ADC), Ovarian cancer.
Shares Mirvetuximab soravtansine, Antibody-drug conjugate (ADC), Ovarian cancer.
Shares Mirvetuximab soravtansine, Antibody-drug conjugate (ADC), Ovarian cancer.
Shares Mirvetuximab soravtansine, Antibody-drug conjugate (ADC), Ovarian cancer.
Shares Mirvetuximab soravtansine, Antibody-drug conjugate (ADC), Ovarian cancer.
Shares Mirvetuximab soravtansine, Antibody-drug conjugate (ADC), Ovarian cancer.
Shares Takeda, Antibody-drug conjugate (ADC).